首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
【24h】

Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.

机译:N-羟基-4-(3-苯基丙酰胺基)苯甲酰胺(HPPB)衍生物作为新型组蛋白脱乙酰基酶抑制剂的设计,合成和初步生物学评估。

获取原文
获取原文并翻译 | 示例
           

摘要

A novel series of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives comprising N-hydroxybenzamide group as zinc-chelating moiety were designed, synthesized and evaluated for their ability to inhibit histone deacetylases. These compounds possessed inhibitory activity against the enzymes with IC(50) values as low as 4.0 microM. Among them, the thiophene substituted derivative 5j (IC(50)=0.3 microM) and benzo[d][1,3]dioxole derivative 5t (IC(50)=0.4 microM) exhibited good antiproliferative activity against the growth of human colon carcinoma cell line HCT116 and non-small cell lung cancer cell (NSCLC) line A549. In addition, they were found to potently induce cell-cycle arrest at G2 phase.
机译:设计,合成和评估了一系列新的N-羟基-4-(3-苯基丙酰胺基)苯甲酰胺(HPPB)衍生物,其包含N-羟基苯甲酰胺基作为锌螯合部分,并抑制了其抑制组蛋白脱乙酰酶的能力。这些化合物具有抑制酶的活性,IC(50)值低至4.0 microM。其中,噻吩取代的衍生物5j(IC(50)= 0.3 microM)和苯并[d] [1,3]二恶唑衍生物5t(IC(50)= 0.4 microM)对人结肠癌的生长具有良好的抗增殖活性。 HCT116细胞系和非小细胞肺癌细胞(NSCLC)A549。此外,发现它们可有效诱导G2期细胞周期停滞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号